P/E ratio for Atossa Therapeutics (ATOS)
P/E ratio as of May 2024 (TTM): -6.08
According to Atossa Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.08. At the end of 2022 the company had a P/E ratio of -2.52.
P/E ratio history for Atossa Therapeutics from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.52 | -71.61% |
| 2021 | -8.89 | 1743.27% |
| 2020 | -0.4822 | -37.34% |
| 2019 | -0.7696 | 955.57% |
| 2018 | -0.0729 | -62.66% |
| 2017 | -0.1953 | -68.15% |
| 2016 | -0.6130 | 1.79% |
| 2015 | -0.6023 | -74.73% |
| 2014 | -2.38 | -30.14% |
| 2013 | -3.41 | -65.3% |
| 2012 | -9.83 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -275.06% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 20.2 | -431.72% | 🇺🇸 USA |
 LabCorp LH | 26.6 | -537.98% | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | N/A | N/A | 🇺🇸 USA |
 NeoGenomics
NEO | -16.0 | 163.16% | 🇺🇸 USA |
 Enzo Biochem ENZ | -1.11 | -81.80% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.